Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies

Volberding, Paul A.; Levine, Alexandra M.; Dieterich, Douglas; Mildvan, Donna; Mitsuyasu, Ronald; Saag, Michael
May 2004
Clinical Infectious Diseases;5/15/2004, Vol. 38 Issue 10, p1454
Academic Journal
Anemia in human immunodeficiency virus (HIV)-infected patients can have serious implications, which vary from functional and quality-of-life decrements to an association with disease progression and decreased survival. In 2002, 16 members of the Anemia in HIV Working Group, an expert panel of physicians involved in the care of HIV-infected patients that met first in 1998, reconvened to assess new data and to translate these data into evidence-based treatment guidelines. The group reached consensus on the prevalence of anemia in the highly active antiretroviral therapy era; the risk factors that are independently associated with the development of anemia; the impact of anemia on quality of life, physical functioning, and survival; the impact of the treatment of hepatitis C virus coinfection on anemia in HIV-infected patients; evidence-based guidelines for treatment of anemia in HIV-infected patients, including the therapeutic role of epoetin alfa; and directions for future research.


Related Articles

  • Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic. Sheng, Wang-Huei; Chen, Mao-Yuan; Hsieh, Szu-Min; Hsiao, Chin-Fu; Wang, Jann-Tay; Hung, Chien-Ching; Chang, Shan-Chwen // Clinical Infectious Diseases;5/15/2004, Vol. 38 Issue 10, p1471 

    Between June 1994 and February 2003, a total of 111 human immunodeficiency virus (HIV)-infected patients with chronic hepatitis B virus (HBV) coinfection and 387 HIV-infected patients without HBV or hepatitis C virus coinfection were prospectively observed to assess the impact of HBV infection...

  • Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) in a Northern Alberta Population. Bowker, Samantha L.; Soskolne, Colin L.; Houston, Stan C.; Newman, Stephen C.; Jhangri, Gian S. // Canadian Journal of Public Health;May/Jun2004, Vol. 95 Issue 3, p188 

    Objective: To describe the demographics and estimate the prevalence of hepatitis C virus (HCV) in a cohort of Human Immunodeficiency Virus (HIV) positive patients in Northern Alberta. Methods: A cross-sectional (prevalence) study was performed on a cohort of HIV-positive patients. HCV testing...

  • Epoetin alfa adds colour in HIV/hep C.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p12 

    Discusses research being done on the effectiveness of epoetin alfa in improving anemia in HIV/hepatitis C virus-coinfected patients. Reference to a study by M. S. Sulkowski and colleagues, published in the August 2005 issue of the "Journal of Acquired Immune Deficiency Syndromes."

  • Drugs to Treat Both HIV, Hepatitis C.  // Guide;Apr2004, Vol. 24 Issue 4, p19 

    Reports that Roche Corp. said a trial of a two-drug combination therapy for HIV-positive persons with hepatitis C virus showed a marked benefit against viral levels. Hepatitis C drug Pegasys and antiviral Copegus; Sustained 40 percent virological response in a trial of 868 patients; Virological...

  • Infection Control in Jails and Prisons. Bick, Joseph A. // Clinical Infectious Diseases;10/15/2007, Vol. 45 Issue 8, p1047 

    At the end of 2005, ∼7 million people (or 1 of every 33 American adults) were either in jail, in prison, or on parole [1]. Compared with the general public, newly incarcerated inmates have an increased prevalence of human immunodeficiency virus infection, hepatitis B virus infection,...

  • A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease. Slim, J; Scangarello, N; Samaha, P; Dazley, J // International Journal of STD & AIDS;Oct2014, Vol. 25 Issue 11, p830 

    Sustained virologic response rates for hepatitis C virus are difficult to achieve in patients infected with human immunodeficiency virus, especially if they have other poor predictors of response. Rates of sustained virologic response for hepatitis C virus genotype 1 in patients with end stage...

  • CD8+ T Cell Activation in Women Coinfected with Human Immunodeficiency Virus Type 1 and Hepatitis C Virus. Kovacs, Andrea; Al-Harthi, Lena; Christensen, Shawna; Mack, Wendy; Cohen, Mardge; Landay, Alan // Journal of Infectious Diseases;5/15/2008, Vol. 197 Issue 10, p1402 

    Immuneactivation is a hallmark ofhumanimmunodeficiency virus type 1 (HIV-1) infection and impacts innate and adaptive immunity. Individuals coinfected with HIV-1 and hepatitis C virus (HCV) may have increased immune activation early in HIVdisease because of a highHCVantigen load in tissues such...

  • Spontaneous Hepatitis C Virus Clearance in HIV-Infected Patients: New Insights for Improving Management. Bruno, Raffaele; Sacchi, Paolo // Journal of Infectious Diseases;11/1/2008, Vol. 198 Issue 9, p1262 

    The article reflects on the implication of hepatitis C virus to patients in the U.S. It was found that progressive chronic liver disease associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection cause morbidity and mortality in patients infected with HIV. Figures shows that...

  • Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection. Saag, Michael S. // JAMA: Journal of the American Medical Association;7/23/2014, Vol. 312 Issue 4, p347 

    An introduction is presented in which the editor discusses microeconomics, quantum leap mechanics, and the treatment of patients with hepatitis C virus (HCV) and HIV coinfection, published in the July 23/30, 2014 issue of the "Journal of American Medical Association" (JAMA).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics